Amgen stock dipped Monday after an analyst downgraded shares, saying the opportunity for its weight-loss drug is already ...

Amgen has downgraded Amgen from buy to hold saying that the potential for obesity asset MariTide is already included in the ...

Goldman Sachs analyst Salveen Richter has reiterated their bullish stance on AMGN stock, giving a Buy rating yesterday. Salveen Richter has ...

Amgen (NASDAQ: AMGN) stock is up 13% this year but has struggled to break out above a tight trading range in recent months.

The ecosystem of companies competing to develop therapies for weight loss is growing every day, and there's more than one ...

Data readouts over the next six months could set expectations for how the highly lucrative market for weight loss therapies will look in the future.

Despite uncertainty around who will sit in The White House in January and what ramifications they may bring, the industry’s ...

Dividend stocks can be a great way to supplement your portfolio growth from share price gains and inject more cash into your ...

As for Lilly ( LLY ), Bernstein said its outperform rating “hinges on what they can do with the cash they generate from ...

PGIM Jennison Health Sciences Fund released its second quarter 2024 investor letter. A copy of the letter can be downloaded ...

Devarakonda said near-term investor focus is on the upcoming release of Phase 2 data on MariTide, Amgen's answer to Ozempic and Wegovy, the obesity drugs from Novo Nordisk A/S (NVO); and Zepbound ...

DBS analyst Nico Chen has maintained their bullish stance on AMGN stock, giving a Buy rating yesterday. Nico Chen has given his Buy rating due ...